ImmuneBridge
San Francisco, US · Founded 2022 · Delaware corporation · 2 known investors
ImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Founders & leadership
ImmuneBridge was founded in 2022 by Peretz Partensky.
PP
Peretz PartenskyFounder
SA
Stuart Alexander JacobsonExecutive
NH
Nina HorowitzChief Executive Officer
RT
Rui TostoesChief Technology Officer
AJ
Alicia JacksonNamed on SEC filing
Board
DM
Dylan MorrisBoard director
NI
Nadiya IshnazarovaBoard director
OA
CZ
GA
Gregory A. BonfiglioBoard director
TF
Thomas FarrellBoard director
MK
Mary Kim WarrenBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$15.8M disclosed across 2 rounds · 2022–2025
▶$5.6MraisedApr 2025 · 6 investors · BiotechnologyRule 506(b)
▶$5.6MraisedApr 2025 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dylan MorrisDirector
- Nadiya IshnazarovaDirector
- Omri Amirav-DroryDirector
- Alicia JacksonDirector
- Stuart Alexander JacobsonExecutive Officer, Director
- Thomas FarrellDirector
- Offering amount
- $7.1M
- Amount sold
- $5.6M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$10.2MraisedJan 2023 · 15 investors · BiotechnologyRule 506(b)
▶$10.2MraisedJan 2023 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alicia JacksonDirector
- Cheryl ZimberlinDirector
- Gregory A. BonfiglioDirector
- Peretz PartenskyExecutive Officer, Director
- Dylan MorrisDirector
- Mary Kim WarrenDirector
- Offering amount
- $14.2M
- Amount sold
- $10.2M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through ImmuneBridge went on to found or lead other companies.
Competitors · 7
by search overlapImmune-Onc Therapeutics21 shared keywordsImmune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
Immuneering21 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Inmune Bio18 shared keywordsINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
Inimmune17 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
Infinimmune16 shared keywordsInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
Bridgebio16 shared keywordsBridgeBio is a biopharmaceutical company that develops medicines for genetic diseases and cancers driven by specific genetic mutations, with a pipeline spanning conditions such as transthyretin amyloidosis, limb-girdle muscular dystrophy, achondroplasia, and hypoparathyroidism. Its programs range from preclinical stages through to approved therapies.
Immunai16 shared keywordsImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
Companies competing with ImmuneBridge for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does ImmuneBridge do?
- ImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.
- Who founded ImmuneBridge?
- ImmuneBridge was founded by Peretz Partensky in 2022.
- Who are ImmuneBridge's investors?
- ImmuneBridge's investors include NFX, M Ventures.
- How much funding has ImmuneBridge raised?
- ImmuneBridge has disclosed $15.8M raised across 2 rounds.
- Where is ImmuneBridge headquartered?
- ImmuneBridge is headquartered in San Francisco, US.